202 related articles for article (PubMed ID: 33716255)
1. Spontaneous Regression of Blastic Plasmacytoid Dendritic Cell Neoplasm Following Sepsis by Serratia marcescens: A Case Report and Literature Review.
Suzuki A; Abe S; Koyama K; Suzuki S; Nagao M; Kobayashi M; Nomura J; Tsutsumi T; Takeda T; Oka Y; Shirota Y; Takasawa N; Kodera T; Okitsu Y; Takahashi S; Ichinohasama R; Kameoka J
Intern Med; 2021; 60(6):927-933. PubMed ID: 33716255
[TBL] [Abstract][Full Text] [Related]
2. A case of blastic plasmacytoid dendritic cell neoplasm with ecchymotic lesions on the whole body.
Cui XB; Jin J; Pang XL; Li S; Liu CX; Li TT; Peng H; Zhang SM; Li L; Liang WH; Chen YZ; Li F
Int J Clin Exp Pathol; 2014; 7(7):4391-9. PubMed ID: 25120824
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological analysis of 46 cases with CD4
Suzuki Y; Kato S; Kohno K; Satou A; Eladl AE; Asano N; Kono M; Kato Y; Taniwaki M; Akiyama M; Nakamura S
Histopathology; 2017 Dec; 71(6):972-984. PubMed ID: 28795410
[TBL] [Abstract][Full Text] [Related]
4. Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm.
He J; Garcia MB; Connors JS; Nuñez CA; Quesada AE; Gibson A; Roth M; Cuglievan B; Pemmaraju N; McCall D
J Pediatr Hematol Oncol; 2023 Nov; 45(8):e1001-e1004. PubMed ID: 37661300
[TBL] [Abstract][Full Text] [Related]
5. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A; Sweet K
J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
[TBL] [Abstract][Full Text] [Related]
6. Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Ashok Kumar P; Ombada M; Pemmasani G; Tambe A; Banki K; Gentile T
J Investig Med High Impact Case Rep; 2022; 10():23247096221127114. PubMed ID: 36341907
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review.
Wang Y; Xiao L; Yin L; Zhou L; Deng Y; Deng H
Medicine (Baltimore); 2023 Feb; 102(7):e32904. PubMed ID: 36800625
[TBL] [Abstract][Full Text] [Related]
8. IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression.
Tang H; Panse G; Braddock D; Perincheri S; Xu ML; McNiff JM
J Cutan Pathol; 2023 Jul; 50(7):595-600. PubMed ID: 37082914
[TBL] [Abstract][Full Text] [Related]
9. An unusual case of cutaneous blastic plasmacytoid dendritic cell neoplasm with concomitant B-cell lymphoproliferative disorder.
Patel JL; Shetty S; Salama ME
Am J Dermatopathol; 2011 May; 33(3):e31-6. PubMed ID: 20861710
[TBL] [Abstract][Full Text] [Related]
10. A CD56- immunoblastoid variant of blastic plasmacytoid dendritic cell neoplasm.
Aran BM; Duran J; Whittemore D; Gru AA
J Cutan Pathol; 2024 Jan; 51(1):40-44. PubMed ID: 37612885
[TBL] [Abstract][Full Text] [Related]
11. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity.
Lim MS; Lemmert K; Enjeti A
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791132
[TBL] [Abstract][Full Text] [Related]
12. [Successful treatment with biweekly CHOP for bone marrow relapse of blastic plasmacytoid dendritic cell neoplasm].
Ono K; Ise M; Ikebe D; Sato A; Wang X; Sugawara T; Tsujimura H; Itami M; Kumagai K
Rinsho Ketsueki; 2017; 58(2):150-154. PubMed ID: 28321093
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous regression of cutaneous blastic plasmacytoid dendritic cell neoplasm followed by acute monocytic leukemia evolving from myelodysplastic syndrome.
Yasuda H; Takaku T; Tomomatsu J; Hosone M; Tanaka H; Komatsu N
Intern Med; 2014; 53(23):2717-20. PubMed ID: 25447656
[TBL] [Abstract][Full Text] [Related]
14. Cytologic features of blastic plasmacytoid dendritic cell neoplasm involving liver: A case report and literature review.
Ding Y; Yang J; Lindsey K
Diagn Cytopathol; 2021 Feb; 49(2):E80-E83. PubMed ID: 32852895
[TBL] [Abstract][Full Text] [Related]
15. [Blastic plasmacytoid dendritic cell neoplasm: A clinico-pathological retrospective analysis of thirteen cases].
Nong L; Wang W; Liang L; Li D; Li X; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):308-314. PubMed ID: 37042142
[TBL] [Abstract][Full Text] [Related]
16. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review.
Wang Q; Zhao Y; Zang X; Zhou G; Liu Y; Feng Q; Li X; Wang W; Dong X; Liu X; Peng J; Liu C
Ann Hematol; 2024 Mar; 103(3):999-1005. PubMed ID: 38285081
[TBL] [Abstract][Full Text] [Related]
17. Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigenetic modifiers: a case report.
Dang X; Zhou D; Meng L; Bi L
J Int Med Res; 2021 Feb; 49(2):300060520982667. PubMed ID: 33530792
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm.
Hwang K; Park CJ; Jang S; Chi HS; Huh JR; Lee JH; Suh C; Lee KH
Histopathology; 2013 Apr; 62(5):764-70. PubMed ID: 23470050
[TBL] [Abstract][Full Text] [Related]
19. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
Adimora IJ; Wilson NR; Pemmaraju N
Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
[TBL] [Abstract][Full Text] [Related]
20. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
